cirrhosis

1.Objective To understand the variation of serum lipid and apoprotein in posthepatitic cirrhosis and biliary cirrhosis.

摘要目讨病毒性肝炎肝硬化与胆汁性肝硬化之间血脂、载脂蛋白变化及其临床意义。

2.Objective To explore the method of treatment for cirrhosis associated portal hypertension and hepatogenic diabetes.

摘要目讨肝硬化门静脉压症合并肝源性糖尿病治疗方法。

3.Conclusion Saccharic metabolic disorder occurred easily in patient with hepatic cirrhosis，eventually develope into diabetes.

肝硬化患者检测血糖避免漏诊。

4.Four patients with intractable pruritus from primary biliary cirrhosis received 2 seven-hour ECAD sessions one day apart.

四位原发性胆道性肝硬化搔痒病人接受2 次七个小时ECAD ，之间间隔一天；

5.One patient with transversal injury of choledoch voluntarily left the hospital because of occurrence of extrahepatic obstructive biliary cirrhosis after the operations.

1例胆总管横断伤因误诊多次手术,并发胆汁性肝硬化自动出院。

6.Early diagnosis and treatment is of significance for preventing hepatic fibrosis and hepatic cirrhosis development as well as for improving life quality of hepatopath patients.

对肝纤维化进行早期诊断、早期治疗，预防肝硬化发生、发展，对肝病患者生命质量具有重要意义。

7.Objective To explore the therapeutic effect of ascites superfilter concentration and reinfusion method on hepatic cirrhosis patients with refractory ascites.

目讨腹水超滤浓缩腹腔回输治疗顽固性肝硬化腹水效果。

8.Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS.

合并肝硬化慢性丙肝（CHC）患者接受α干扰素包括派罗欣治疗时存在肝功能失代偿和死亡风险。